Back to results
US 9,751,921 B2Granted
Apelin fusion proteins and uses thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsPanayiotis Stevis, Andrew Murphy
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsPanayiotis Stevis, Andrew Murphy
Estimating the term…
The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or a variant of an Fc domain. Apelin Fc-fusion polypeptides are capable of binding to the apelin receptor (APLNR). Apelin Fc-fusion polypeptides are capable of activating the APLNR and have improved pharmacokinetic properties compared to apelin peptides that are not fused to an Fc or an Fc fragment. Apelin Fc-fusion polypeptides are useful in diseases and conditions related to cardiovascular function, diabetes, cancer, obesity and other apelin-related conditions.
A polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or variant of an Fc domain, wherein the N-terminus of the apelin peptide is fused to the C-terminus of the Fc domain or fragment or variant thereof, optionally via a peptide linker, and wherein the apelin peptide is a modified apelin 65-77 (apelin-13) peptide having an additional natural amino acid at its C-terminus.
A polypeptide comprising the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.